|Last Price$3.11||Day Change (%)1.97%|
|Open Price$3.09||Day Change ($)0.06|
|Day Range3.00–3.16||52-Week Range1.26–7.40|
As of Thu 3/5/2015 5:00:00 PM | USD
Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Research and Markets: Cabozantinib - Comprehensive Patent Search Portal
UPDATE: These are the most profitable Nasdaq biotech companies
UPDATE: These are the most profitable Nasdaq -2-
Compugen Expands and Strengthens Business Development Team
Roche Gets FDA Priority Review for Cancer Treatment
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Research and Markets: Global Agriculture Farm Equipment Industry (2013-2018)
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.